GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curative Biotechnology Inc (OTCPK:CUBT) » Definitions » Float Percentage Of Total Shares Outstanding

Curative Biotechnology (Curative Biotechnology) Float Percentage Of Total Shares Outstanding : 0.00% (As of Jun. 02, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Curative Biotechnology Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Curative Biotechnology's float shares is 0.00 Mil. Curative Biotechnology's total shares outstanding is 903.26 Mil. Curative Biotechnology's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Curative Biotechnology's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Curative Biotechnology's Institutional Ownership is 0.00%.


Curative Biotechnology Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Curative Biotechnology's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/903.26
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Curative Biotechnology (Curative Biotechnology) Business Description

Industry
Traded in Other Exchanges
N/A
Address
1825 NW Corporate Boulevard, Suite 110, Boca Raton, FL, USA, 33431
Curative Biotechnology Inc is a development-stage biomedical company focusing on novel treatments for rare diseases. The company currently has ongoing programs in three therapeutic areas: Infectious Disease, Neuro-Oncology, and Degenerative Eye Disease.